Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial2019년 코로나바이러스 질환 입원 환자에서 사릴루맙의 효능 및 안전성: 무작위 임상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, [키워드] 95% CI 95% confidence interval adaptive adults hospitalized analysis anti-IL-6R monoclonal antibody baseline benefit clinical clinical status coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids corticosteroids) COVID-19 Critical death double-blind Efficacy Efficacy and safety evaluated hazard ratio Hospitalized hospitalized patient hospitalized patients interleukin interleukin-6 interleukin-6 receptor intravenous mechanical ventilation Meta-analysis monoclonal antibodies monoclonal antibodies. Patient patients randomized Phase 2 phase 2/3 Phase 3 Placebo placebo-controlled trial Platform trial Post hoc analyses Post hoc analysis primary analysis population Primary outcome proportion Randomized receiving Relative risk risk risk difference Safety sarilumab therapy treated Treatment Trial with COVID-19 [DOI] 10.1093/cid/ciac153 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative GroupCOVID-19 폐렴이 있는 위독한 성인 환자에서 인터루킨-6 수용체 길항제의 효과: CORIMUNO-19 공동 그룹의 2건의 무작위 대조 시험Article Published on 2022-08-102022-09-11 Journal: The European Respiratory Journal [Category] Fulltext, SARS, 임상, [키워드] 95% CI antagonist anti-IL-6 receptor assigned Bayesian clinical trials clinically controlled clinical trials coronavirus disease Coronavirus disease 2019 COVID-19 credible interval CrI Critically ill Critically ill patient critically ill patients determine Effect events group hazard ratio IMPROVE indicated interleukin-6 receptor intravenously investigator-initiated mechanical ventilation median multicentre NIV Noninvasive ventilation not need numbers of patient Open-label outcome Patient patients with COVID-19 Pneumonia posterior probability randomised randomised controlled randomised controlled trial Randomly receive receptor risk of death SARI sarilumab significantly TCZ TOCI Tocilizumab Trial usual care with COVID-19 [DOI] 10.1183/13993003.02523-2021 PMC 바로가기 [Article Type] Article
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis코로나19로 입원한 환자에서 토실리주맙, 사릴루맙, 28일 후 모든 원인 사망률 사이의 연관성: 네트워크 메타 분석Meta-Analysis Published on 2022-07-082022-09-11 Journal: PLoS ONE [Category] meta-analysis, 임상, 진단, [키워드] 28-day mortality all-cause mortality antagonist association choice clinician Consistency Corticosteroid Corticosteroids COVID-19 patient deaths demonstrated dependent on Effect eligible patient Evidence hospitalised patient Hospitalised patients in-hospital mortality inconsistency initiated interleukin-6 interleukin-6 receptor invasive ventilation Meta-analysis Network meta-analysis Non-invasive not dependent Odds ratio Odds ratios P-value Patient Placebo randomisation randomised randomised comparison receiving receptor antagonist REMAP-CAP REMAP-CAP trial sarilumab Tocilizumab Trial usual care Ventilation with COVID-19 [DOI] 10.1371/journal.pone.0270668 PMC 바로가기 [Article Type] Meta-Analysis
Tocilizumab and COVID-19: Timing of Administration and EfficacyPharmacology Published on 2022-02-182022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] “cytokine storm” acute respiratory distress syndrome Admission Concentration Corticosteroids COVID-19 COVID-19 infection COVID-19 pandemic Cytokine storm demonstrated described Effect Efficacy and safety Evidence highlighting Host humanized monoclonal antibody immune immune dysregulation immunomodulatory impairment Infection intensive care intensive care unit interleukin-6 interleukin-6 receptor interleukine -6 receptor antagonist Intervention Invasive mechanical ventilation investigated key factor mechanical ventilation Mortality observational study outcome pathophysiology patients patients with COVID-19 Pneumonia positive result Potential treatment Prognostic factor Proinflammatory response Randomized controlled trial reported risk SARS-COV-2 infection selected shown Standard of care Support therapy Tocilizumab with COVID-19 [DOI] 10.3389/fphar.2022.825749 PMC 바로가기 [Article Type] Pharmacology
Therapeutic implications of ongoing alveolar viral replication in COVID-19Review article Published on 2022-02-012022-10-05 Journal: The Lancet Rheumatology [Category] 변종, [키워드] alveolar approach autoimmune responses benefit blunting Corticosteroid COVID-19 Critical disease disease excessive inflammatory response heterogeneity highlight immunomodulatory therapy immunopathology Immunosuppression Immunotherapy immunothrombosis implication individual innate immune response interleukin-6 receptor Lungs Mild moderate-to-severe COVID-19 moderate-to-severe COVID-19 pneumonia Oxygen therapy Patient patients treated SARS-CoV-2 clearance SARS-CoV-2 replication T-cell responses therapeutic therapy thought Ventilation viral replication [DOI] 10.1016/S2665-9913(21)00322-2 [Article Type] Review article
Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination백신 접종 전 서부 자카르타의 사립 병원에서 사이토카인 폭풍이 COVID-19 질병의 중증도에 미치는 영향Research Article Published on 2022-01-252022-09-12 Journal: PLoS ONE [Category] 진단, [키워드] Administered Admission age Antibiotics Azithromycin B-complex Clinical outcome Cold Combination combination treatment Comorbidity contrary convenience sampling coronavirus disease Coronavirus disease 2019 correlation cough COVID-19 COVID-19 disease COVID-19 patient COVID-19 patients COVID-19 positive patient Critical Critically ill critically ill patients cured Cytokine storm Cytokine storms diabete diabetes died disease duration of treatment effective therapy enrolled Factor fatigue Favipiravir Fever global health Health high mortality rate hospital Hospitalized Hydroxychloroquine hypertension ICU Immunoglobulin Impact include inclusion criteria Indonesia injection intensive care intensive care unit interleukin-6 interleukin-6 receptor investigated Jakarta less levofloxacin material mineral Minerals Ministry of Health MOST Most patient Most patients oseltamivir oxygen oxygen saturation Patient patients died plasma Private receiving receptor antagonist Remdesivir reported Result retrospective cohort study severity of COVID-19 Severity of infection Shortness of breath SpO2 survival rate survived Symptom Symptoms the cytokine storm therapy Tocilizumab treat treated Treatment utilised vaccination Vitamin vitamins vitamins C was used West worldwide pandemic [DOI] 10.1371/journal.pone.0262438 PMC 바로가기 [Article Type] Research Article
In Silico Studies on Psilocybin Drug Derivatives Against SARS-CoV-2 and Cytokine Storm of Human Interleukin-6 ReceptorSARS-CoV-2 및 인간 인터루킨-6 수용체의 사이토카인 폭풍에 대한 실로시빈 약물 유도체에 대한 실리코 연구Immunology Published on 2022-01-142022-09-11 Journal: Frontiers in Immunology [Category] SARS, 치료제, [키워드] Against Antibacterial anticancer Antiviral binding change chemotherapeutic agent chemotherapeutic agents Compound COVID-19 cytokine Cytokine storm derivative drug free energy Gibbs free energy Human inhibit inhibitors inhibitors of SARS-CoV-2 interleukin-6 interleukin-6 receptor malignancy metabolite Mprotease mushroom over Proteins psilocin psilocybin psilocybine reduce SARS-CoV-2 screened storm suggested therapeutic [DOI] 10.3389/fimmu.2021.794780 PMC 바로가기 [Article Type] Immunology
Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemicCOVID-19 전염병 초기에 오프라벨 토실리주맙 사용을 알리기 위한 현지 데이터의 신속한 분석Randomized Controlled Trial Published on 2021-12-012022-09-12 Journal: Healthcare (Amsterdam, Netherlands) [Category] SARS, 임상, 진단, [키워드] absence Algorithm Analysis clinical benefit Clinical outcome coronavirus disease COVID-19 COVID-19 pandemic COVID-19 patient Cytokine release syndrome disseminate Evidence-based decision-making hospitalized COVID-19 patient hyperinflammatory state interleukin 6 interleukin 6 (IL-6) interleukin-6 receptor Local observational study off-label pandemic performed randomized clinical trial Rapid SARS-CoV-2 suggested Tocilizumab tocilizumab. treated Treatment [DOI] 10.1016/j.hjdsi.2021.100581 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registryRandomized Controlled Trial Published on 2021-10-022022-10-04 Journal: European Journal of Medical Research [Category] MERS, SARS, 임상, [키워드] 28-day mortality 95% CI 95% confidence interval adjusted adjusted odds ratio administration antagonist Bacteremia C-reactive protein Characteristics clinical Clinical characteristics clinical outcomes cohort study collected Combination combination therapy combinations conducted coronavirus disease Coronavirus disease 2019 Corticosteroid COVID-19 COVID-19 patient COVID-19 patients Critical Critical care Critically ill Dexamethasone Discordance dose driver dysfunction eligibility criteria ENhance Epidemiology evaluate Evidence groups help High-dose Hyperinflammatory ICU admission identify illness immunomodulatory therapy incidence rate interleukin-6 interleukin-6 receptor Interleukin-6 receptor antagonist interquartile Invasive mechanical ventilation low-dose majority material mechanically ventilated median median age Medicine multicenter network not differ outcome Patient phenotype preliminary report Randomized controlled trial receiving receptor recommendations regimens respiratory Result sarilumab Society steroid Steroids supplementary material the patient the timing therapy Tocilizumab university Variation Ventilator-free days [DOI] 10.1186/s40001-021-00591-x PMC 바로가기 [Article Type] Randomized Controlled Trial
COVID-19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease-specific drug신장 이식 환자의 코로나19 폐렴: 질병별 약물 부재 시 유망한 치료 알고리즘Article Published on 2021-10-012022-09-12 Journal: Journal of medical virology [Category] MERS, SARS, 진단, [키워드] absence administration Algorithm Anti-inflammatory anti-inflammatory treatment Antibiotics antibody applied CCT Chest computed tomography Clinical outcome composed Consensus coronavirus disease COVID-19 Deceased diagnosed with COVID-19 disease evaluated examined Favipiravir High-dose Hospitalized hospitals immunosuppressive interleukin-6 receptor Intravenous immunoglobulin intravenous methylprednisolone IVIG kidney kidney transplant kidney transplant recipient Kidney transplantation management Modification mortality rate Nonresponder Organ transplant outcomes parameter Patient patients patients with pneumonia Pneumonia pneumonia. protocol provided receive required respiratory Respiratory failure Safe Severe COVID-19 pneumonia significantly therapy Tocilizumab treated Treatment Treatment protocol were given with COVID-19 [DOI] 10.1002/jmv.27110 PMC 바로가기 [Article Type] Article